Nifluril Enfants (Morniflumate)

Morniflumate, the active ingredient in Nifluril Enfants, is a fenamate NSAID presented as a rectal formulation for rectal use. It is employed to relieve pain and inflammation associated with musculoskeletal disorders in children and adolescents, providing anti‑inflammatory and analgesic effects where oral options are unsuitable.

GNH USA supplies Nifluril Enfants as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution across the European Union and other regulated markets. The company ensures quality and regulatory compliance throughout the supply chain.

Morniflumate is used to manage conditions involving pain and inflammation within the musculoskeletal system.

- Pain: Reduces acute and chronic pain associated with musculoskeletal injuries. - Inflammation: Decreases inflammatory swelling in joints and soft tissues. - Musculoskeletal disorders: Improves functional mobility and comfort in conditions such as sprains, strains and juvenile arthritis.

Morniflumate may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Gastrointestinal irritation: mild abdominal discomfort or dyspepsia. - Nausea: occasional feeling of queasiness. - Headache: transient mild headache. - Local irritation: mild rectal burning or itching.

Serious or Rare Side Effects: - Ulceration or bleeding: gastrointestinal ulcer or hemorrhage. - Hepatotoxicity: elevated liver enzymes or liver injury. - Renal impairment: reduced kidney function or acute renal failure. - Severe allergic reaction: rash, angioedema or anaphylaxis.

When prescribing Morniflumate, several precautions should be observed to minimise risk. - Assess renal function: evaluate kidney status before initiating therapy. - Monitor hepatic health: check liver enzymes in patients with liver disease. - Use caution in elderly: increased susceptibility to NSAID‑related adverse events. - Avoid concurrent ulcerogenic drugs: limit use with other NSAIDs, corticosteroids or anticoagulants. - Pregnancy and lactation: contraindicated or use only if benefits outweigh risks. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Morniflumate can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Other NSAIDs: additive risk of gastrointestinal bleeding. - Anticoagulants (e.g., warfarin): increased bleeding tendency. - Corticosteroids: heightened ulcer risk.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: possible reduction in renal function. - Diuretics: risk of electrolyte imbalance and renal impairment. - Lithium: increased lithium levels leading to toxicity.